NewsLepton announces filing of a US PCT application covering its proprietary breakthrough TRIPLE Technology
Lepton Pharmaceuticals announces that it has filed a US application with the US Patent Office entitled METHODS FOR ENHANCED GENOME EDITING The Patent application covers Lepton’s breakthrough Universal genome editing framework. It is a novel homology directed repair (HDR)-based knock-in (KI) technology named Targeted Replacement Locus Editing (TRIPLE). Precise genome editing is limited by the...